ACE and type 2 diabetes mellitus: Individual drugs—antiplatelets/anticoagulants, beta-blockers, ACE- or angiotensin receptor inhibitors and lipid lowering drugs—were prescribed, but only 52% of the patients with newly detected dysglycaemia and just 48% of those with known T2DM received all four drug classes, which are all important for mortality reduction [27].